Research led by Memorial Sloan Kettering Cancer Center (MSK) is shedding new light on how ovarian cancer evolves—insights ...

New preclinical research shows a promising drug combination that targets ovarian cancer’s survival pathways, paving the way ...

Most prostate cancer is slow-growing and treatable. But one type that’s rare is often deadly. Learn about transitional cell or urothelial carcinoma.

Ovarian cancer can cause white blood cell levels to go up. However, white blood cell counts are not an effective diagnostic tool for this disease.

These rare ovarian cancers can be hard to spot early. Learn the signs of ovarian germ cell tumors and what to do if you suspect you have one.

Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have improved survival following immunotherapy compared to patients without ...

Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma The following represents disclosure information provided by authors of this manuscript. All relationships are ...

They seeded ovarian cancer cells on top of the mesothelial cell layer and compared what effect the arrangement of the mesothelial cells had on how the tumor cells passed through this barrier.

A study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development can benefit patients with late-stage, drug-resistant ovarian cancer.